Dietary iron enters the mucosal cells in our intestine in the ferrous form (iron (II)). The simplest medication for oral iron supplementation is in the form of ferrous salts with ferrous sulphate being its most common representative. Ferrous sulphate is efficacious, inexpensive to manufacture, but has some significant tolerability and safety issues thought to derive from surplus iron delivery. Vifor Pharma„s research and development applied their leading expertise in iron replacement therapy to improving the control of oral iron delivery while at least maintaining efficacy of ferrous sulphate. The result is Maltofer® with its unique stable iron (III) polymaltose complex that ensures a controlled iron uptake. As a consequence, patients with iron deficiency and without or with anaemia (ID(A)) taking Maltofer® are less likely to experience gastrointestinal side effects seen with iron (II) preparations. Maltofer® effectively corrects haemoglobin levels in patients with ID(A). Unlike iron (II) preparations, Maltofer® fits easily into the patient„s daily routine because: - It does not react with food components and is indicated to be taken with food - It has a pleasant taste - It does not interact with most standard co-medications - It is available in a variety of formulations Overall, Maltofer® is well accepted by patients and shows improved adherence across different patient populations.
Posted on: Thu, 04 Jul 2013 10:49:46 +0000
Trending Topics
Recently Viewed Topics
© 2015